

conditions to allow specific binding;

BL

- b) recovering the bound protein; and
- d) separating the protein from the molecule or compound, thereby obtaining purified molecule or compound.

REMARKS

Justification for the amendments is as follows. The above amendments correct inadvertent typographical and grammatical errors in the specification. Support for the amendment to claim 1 is found, for example, at page 42, lines 17-22 and for new claim 22 at page 27, line 26 through page 29, line 15. Support for new claims 23-24 is found, for example, at page 11, lines 24-29 (peptide nucleic acids), at page 17, lines 20-25 (nucleic acids), at page 18, lines 26-30 (peptides), at page 26, lines 2-20 (antibodies, immunoglobulins), at page 27, lines 23-25 (pharmaceutical agents), at page 32, lines 5-6 (mimetics, agonists, antagonists, inhibitors), at page 43, lines 2-5 (drug compounds), and at page 52, lines 2-7 (binding assays). Support for new claim 25 is found at page 12, lines 10-16 and at page 13, lines 4-7. No new matter has been added by these amendments. Applicants respectfully request entry of the present amendment.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date: November 14, 1999

David G. Streeter

David G. Streeter, Ph. D.

Reg. No. 43,168

Direct Dial Telephone: (650) 845-5741

3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886